Review





Similar Products

proteomic analyses  (Genechem)
86
Genechem proteomic analyses
CMKLR1 knockdown suppresses mitochondrial OXPHOS in OSCC cells. (A) Volcano plot of DEPs in CMKLR1-knockdown and control Cal-27 cells, depicting upregulated proteins (red), downregulated proteins (blue), and nonsignificant proteins (gray). (B) Heatmap of the top DEPs identified through <t>proteomic</t> analysis. (C) Subcellular localization pie chart of DEPs, revealing a large proportion localized to mitochondria. (D, E) GO and KEGG pathway enrichment analyses of DEPs, highlighting enrichment in OXPHOS-related processes. (F) Gene set enrichment analysis demonstrating the significant downregulation of OXPHOS in CMKLR1-silenced cells. (G) Seahorse XF analysis of mitochondrial respiration indicating a reduced OCR in CMKLR1-knockdown OSCC cells. (H) Quantification of basal respiration, ATP production, maximal respiration, and spare respiratory capacity in CMKLR1-knockdown cells. (I) Western blot analysis of representative OXPHOS complex subunits (CI-NDUFB8, CII-SDHB, CIII-UQCRC1, CIV-MTCO2, and CV-ATP5A1), with β-actin as loading control. (J) Representative MitoTracker images and quantification of fluorescence intensity (MitoTracker Red, scale bar = 20 μm). * P < .05; ** P < .01; *** P < .001.
Proteomic Analyses, supplied by Genechem, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/proteomic+analyses/pmc13011209-117-1-6?v=Genechem
Average 86 stars, based on 1 article reviews
proteomic analyses - by Bioz Stars, 2026-07
86/100 stars
  Buy from Supplier
proteomic analyses  (Novogene)
86
Novogene proteomic analyses
Study design and global multi-omics profiling of patients with VP and VAPA. (A) Schematic overview of the study design and patient grouping. (B) Principal component analysis (PCA) of plasma <t>proteomic</t> datasets. Each dot represents an individual plasma sample and different colors denote different patient groups. (C) Volcano plots of differentially expressed proteins between the VP and VAPA groups. Red points indicate significantly increased features, blue points indicate significantly decreased features, and gray points represent features with no significant differences. (D) Principal component analysis (PCA) of plasma metabolomic datasets. Each dot represents an individual plasma sample and different colors denote different patient groups. (E) Volcano plots of differentially expressed metabolites between the VP and VAPA groups. Red points indicate significantly increased features, blue points indicate significantly decreased features, and gray points represent features with no significant differences.
Proteomic Analyses, supplied by Novogene, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/proteomic+analyses/pmc13253414-130-1-6?v=Novogene
Average 86 stars, based on 1 article reviews
proteomic analyses - by Bioz Stars, 2026-07
86/100 stars
  Buy from Supplier
proteomic analyses  (Creative Proteomics)
86
Creative Proteomics proteomic analyses
Study design and global multi-omics profiling of patients with VP and VAPA. (A) Schematic overview of the study design and patient grouping. (B) Principal component analysis (PCA) of plasma <t>proteomic</t> datasets. Each dot represents an individual plasma sample and different colors denote different patient groups. (C) Volcano plots of differentially expressed proteins between the VP and VAPA groups. Red points indicate significantly increased features, blue points indicate significantly decreased features, and gray points represent features with no significant differences. (D) Principal component analysis (PCA) of plasma metabolomic datasets. Each dot represents an individual plasma sample and different colors denote different patient groups. (E) Volcano plots of differentially expressed metabolites between the VP and VAPA groups. Red points indicate significantly increased features, blue points indicate significantly decreased features, and gray points represent features with no significant differences.
Proteomic Analyses, supplied by Creative Proteomics, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/proteomic+analyses/pm42108503-62-12-26?v=Creative+Proteomics
Average 86 stars, based on 1 article reviews
proteomic analyses - by Bioz Stars, 2026-07
86/100 stars
  Buy from Supplier
proteomic analyses  (Sangon Biotech)
86
Sangon Biotech proteomic analyses
Study design and global multi-omics profiling of patients with VP and VAPA. (A) Schematic overview of the study design and patient grouping. (B) Principal component analysis (PCA) of plasma <t>proteomic</t> datasets. Each dot represents an individual plasma sample and different colors denote different patient groups. (C) Volcano plots of differentially expressed proteins between the VP and VAPA groups. Red points indicate significantly increased features, blue points indicate significantly decreased features, and gray points represent features with no significant differences. (D) Principal component analysis (PCA) of plasma metabolomic datasets. Each dot represents an individual plasma sample and different colors denote different patient groups. (E) Volcano plots of differentially expressed metabolites between the VP and VAPA groups. Red points indicate significantly increased features, blue points indicate significantly decreased features, and gray points represent features with no significant differences.
Proteomic Analyses, supplied by Sangon Biotech, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/proteomic+analyses/pm41843539-432-11-4?v=Sangon+Biotech
Average 86 stars, based on 1 article reviews
proteomic analyses - by Bioz Stars, 2026-07
86/100 stars
  Buy from Supplier
untargeted proteomics analyses  (Evosep Biosystems)
86
Evosep Biosystems untargeted proteomics analyses
Study design and global multi-omics profiling of patients with VP and VAPA. (A) Schematic overview of the study design and patient grouping. (B) Principal component analysis (PCA) of plasma <t>proteomic</t> datasets. Each dot represents an individual plasma sample and different colors denote different patient groups. (C) Volcano plots of differentially expressed proteins between the VP and VAPA groups. Red points indicate significantly increased features, blue points indicate significantly decreased features, and gray points represent features with no significant differences. (D) Principal component analysis (PCA) of plasma metabolomic datasets. Each dot represents an individual plasma sample and different colors denote different patient groups. (E) Volcano plots of differentially expressed metabolites between the VP and VAPA groups. Red points indicate significantly increased features, blue points indicate significantly decreased features, and gray points represent features with no significant differences.
Untargeted Proteomics Analyses, supplied by Evosep Biosystems, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/proteomic+analyses/pmc13026406-97-15-26?v=Evosep+Biosystems
Average 86 stars, based on 1 article reviews
untargeted proteomics analyses - by Bioz Stars, 2026-07
86/100 stars
  Buy from Supplier
mass spectrometry based proteomic analyses  (Novo Nordisk)
86
Novo Nordisk mass spectrometry based proteomic analyses
Study design and global multi-omics profiling of patients with VP and VAPA. (A) Schematic overview of the study design and patient grouping. (B) Principal component analysis (PCA) of plasma <t>proteomic</t> datasets. Each dot represents an individual plasma sample and different colors denote different patient groups. (C) Volcano plots of differentially expressed proteins between the VP and VAPA groups. Red points indicate significantly increased features, blue points indicate significantly decreased features, and gray points represent features with no significant differences. (D) Principal component analysis (PCA) of plasma metabolomic datasets. Each dot represents an individual plasma sample and different colors denote different patient groups. (E) Volcano plots of differentially expressed metabolites between the VP and VAPA groups. Red points indicate significantly increased features, blue points indicate significantly decreased features, and gray points represent features with no significant differences.
Mass Spectrometry Based Proteomic Analyses, supplied by Novo Nordisk, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/proteomic+analyses/pm41546080-275-0-23?v=Novo+Nordisk
Average 86 stars, based on 1 article reviews
mass spectrometry based proteomic analyses - by Bioz Stars, 2026-07
86/100 stars
  Buy from Supplier
proteomic sequencing analyses  (Bioprofile Testing)
86
Bioprofile Testing proteomic sequencing analyses
Study design and global multi-omics profiling of patients with VP and VAPA. (A) Schematic overview of the study design and patient grouping. (B) Principal component analysis (PCA) of plasma <t>proteomic</t> datasets. Each dot represents an individual plasma sample and different colors denote different patient groups. (C) Volcano plots of differentially expressed proteins between the VP and VAPA groups. Red points indicate significantly increased features, blue points indicate significantly decreased features, and gray points represent features with no significant differences. (D) Principal component analysis (PCA) of plasma metabolomic datasets. Each dot represents an individual plasma sample and different colors denote different patient groups. (E) Volcano plots of differentially expressed metabolites between the VP and VAPA groups. Red points indicate significantly increased features, blue points indicate significantly decreased features, and gray points represent features with no significant differences.
Proteomic Sequencing Analyses, supplied by Bioprofile Testing, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/proteomic+analyses/pm41387425-416-25-17?v=Bioprofile+Testing
Average 86 stars, based on 1 article reviews
proteomic sequencing analyses - by Bioz Stars, 2026-07
86/100 stars
  Buy from Supplier
timstof pro mass spectrometer proteomics analyses  (Bruker Corporation)
99
Bruker Corporation timstof pro mass spectrometer proteomics analyses
Study design and global multi-omics profiling of patients with VP and VAPA. (A) Schematic overview of the study design and patient grouping. (B) Principal component analysis (PCA) of plasma <t>proteomic</t> datasets. Each dot represents an individual plasma sample and different colors denote different patient groups. (C) Volcano plots of differentially expressed proteins between the VP and VAPA groups. Red points indicate significantly increased features, blue points indicate significantly decreased features, and gray points represent features with no significant differences. (D) Principal component analysis (PCA) of plasma metabolomic datasets. Each dot represents an individual plasma sample and different colors denote different patient groups. (E) Volcano plots of differentially expressed metabolites between the VP and VAPA groups. Red points indicate significantly increased features, blue points indicate significantly decreased features, and gray points represent features with no significant differences.
Timstof Pro Mass Spectrometer Proteomics Analyses, supplied by Bruker Corporation, used in various techniques. Bioz Stars score: 99/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/proteomic+analyses/pmc12790720-217-12-11?v=Bruker+Corporation
Average 99 stars, based on 1 article reviews
timstof pro mass spectrometer proteomics analyses - by Bioz Stars, 2026-07
99/100 stars
  Buy from Supplier
gastroenterology proteomic analyses  (Wolters Kluwer Health)
86
Wolters Kluwer Health gastroenterology proteomic analyses
Study design and global multi-omics profiling of patients with VP and VAPA. (A) Schematic overview of the study design and patient grouping. (B) Principal component analysis (PCA) of plasma <t>proteomic</t> datasets. Each dot represents an individual plasma sample and different colors denote different patient groups. (C) Volcano plots of differentially expressed proteins between the VP and VAPA groups. Red points indicate significantly increased features, blue points indicate significantly decreased features, and gray points represent features with no significant differences. (D) Principal component analysis (PCA) of plasma metabolomic datasets. Each dot represents an individual plasma sample and different colors denote different patient groups. (E) Volcano plots of differentially expressed metabolites between the VP and VAPA groups. Red points indicate significantly increased features, blue points indicate significantly decreased features, and gray points represent features with no significant differences.
Gastroenterology Proteomic Analyses, supplied by Wolters Kluwer Health, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/proteomic+analyses/pm41134301-72-13-2?v=Wolters+Kluwer+Health
Average 86 stars, based on 1 article reviews
gastroenterology proteomic analyses - by Bioz Stars, 2026-07
86/100 stars
  Buy from Supplier

Image Search Results


CMKLR1 knockdown suppresses mitochondrial OXPHOS in OSCC cells. (A) Volcano plot of DEPs in CMKLR1-knockdown and control Cal-27 cells, depicting upregulated proteins (red), downregulated proteins (blue), and nonsignificant proteins (gray). (B) Heatmap of the top DEPs identified through proteomic analysis. (C) Subcellular localization pie chart of DEPs, revealing a large proportion localized to mitochondria. (D, E) GO and KEGG pathway enrichment analyses of DEPs, highlighting enrichment in OXPHOS-related processes. (F) Gene set enrichment analysis demonstrating the significant downregulation of OXPHOS in CMKLR1-silenced cells. (G) Seahorse XF analysis of mitochondrial respiration indicating a reduced OCR in CMKLR1-knockdown OSCC cells. (H) Quantification of basal respiration, ATP production, maximal respiration, and spare respiratory capacity in CMKLR1-knockdown cells. (I) Western blot analysis of representative OXPHOS complex subunits (CI-NDUFB8, CII-SDHB, CIII-UQCRC1, CIV-MTCO2, and CV-ATP5A1), with β-actin as loading control. (J) Representative MitoTracker images and quantification of fluorescence intensity (MitoTracker Red, scale bar = 20 μm). * P < .05; ** P < .01; *** P < .001.

Journal: International Dental Journal

Article Title: Chemokine-Like Receptor 1 Knockdown Suppresses Oral Squamous Cell Carcinoma Progression by Reducing Oxidative Phosphorylation

doi: 10.1016/j.identj.2026.109479

Figure Lengend Snippet: CMKLR1 knockdown suppresses mitochondrial OXPHOS in OSCC cells. (A) Volcano plot of DEPs in CMKLR1-knockdown and control Cal-27 cells, depicting upregulated proteins (red), downregulated proteins (blue), and nonsignificant proteins (gray). (B) Heatmap of the top DEPs identified through proteomic analysis. (C) Subcellular localization pie chart of DEPs, revealing a large proportion localized to mitochondria. (D, E) GO and KEGG pathway enrichment analyses of DEPs, highlighting enrichment in OXPHOS-related processes. (F) Gene set enrichment analysis demonstrating the significant downregulation of OXPHOS in CMKLR1-silenced cells. (G) Seahorse XF analysis of mitochondrial respiration indicating a reduced OCR in CMKLR1-knockdown OSCC cells. (H) Quantification of basal respiration, ATP production, maximal respiration, and spare respiratory capacity in CMKLR1-knockdown cells. (I) Western blot analysis of representative OXPHOS complex subunits (CI-NDUFB8, CII-SDHB, CIII-UQCRC1, CIV-MTCO2, and CV-ATP5A1), with β-actin as loading control. (J) Representative MitoTracker images and quantification of fluorescence intensity (MitoTracker Red, scale bar = 20 μm). * P < .05; ** P < .01; *** P < .001.

Article Snippet: All proteomic analyses were conducted by GeneChem (Shanghai, China).

Techniques: Knockdown, Control, Western Blot, Fluorescence

Study design and global multi-omics profiling of patients with VP and VAPA. (A) Schematic overview of the study design and patient grouping. (B) Principal component analysis (PCA) of plasma proteomic datasets. Each dot represents an individual plasma sample and different colors denote different patient groups. (C) Volcano plots of differentially expressed proteins between the VP and VAPA groups. Red points indicate significantly increased features, blue points indicate significantly decreased features, and gray points represent features with no significant differences. (D) Principal component analysis (PCA) of plasma metabolomic datasets. Each dot represents an individual plasma sample and different colors denote different patient groups. (E) Volcano plots of differentially expressed metabolites between the VP and VAPA groups. Red points indicate significantly increased features, blue points indicate significantly decreased features, and gray points represent features with no significant differences.

Journal: Frontiers in Cellular and Infection Microbiology

Article Title: Amplified inflammatory and immune responses in viral-associated pulmonary aspergillosis

doi: 10.3389/fcimb.2026.1850127

Figure Lengend Snippet: Study design and global multi-omics profiling of patients with VP and VAPA. (A) Schematic overview of the study design and patient grouping. (B) Principal component analysis (PCA) of plasma proteomic datasets. Each dot represents an individual plasma sample and different colors denote different patient groups. (C) Volcano plots of differentially expressed proteins between the VP and VAPA groups. Red points indicate significantly increased features, blue points indicate significantly decreased features, and gray points represent features with no significant differences. (D) Principal component analysis (PCA) of plasma metabolomic datasets. Each dot represents an individual plasma sample and different colors denote different patient groups. (E) Volcano plots of differentially expressed metabolites between the VP and VAPA groups. Red points indicate significantly increased features, blue points indicate significantly decreased features, and gray points represent features with no significant differences.

Article Snippet: All proteomic analyses were performed by Novogene Co., Ltd. (Beijing, China).

Techniques: Biomarker Discovery, Clinical Proteomics, Metabolomic

Plasma proteomic profiles of patients with VP and VAPA. (A) Bar chart showing functional classification of all identified plasma proteins. (B) Hierarchical clustering heatmap of proteins that are differentially expressed between patients with VP and VAPA. Columns represent individual plasma samples, and rows represent differentially expressed proteins. Color intensity from blue to red indicates relative protein abundance ranging from low to high.

Journal: Frontiers in Cellular and Infection Microbiology

Article Title: Amplified inflammatory and immune responses in viral-associated pulmonary aspergillosis

doi: 10.3389/fcimb.2026.1850127

Figure Lengend Snippet: Plasma proteomic profiles of patients with VP and VAPA. (A) Bar chart showing functional classification of all identified plasma proteins. (B) Hierarchical clustering heatmap of proteins that are differentially expressed between patients with VP and VAPA. Columns represent individual plasma samples, and rows represent differentially expressed proteins. Color intensity from blue to red indicates relative protein abundance ranging from low to high.

Article Snippet: All proteomic analyses were performed by Novogene Co., Ltd. (Beijing, China).

Techniques: Clinical Proteomics, Functional Assay, Quantitative Proteomics